Welcome to our dedicated page for Pure Bioscience SEC filings (Ticker: PURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the science behind Pure Bioscience’s silver dihydrogen citrate platform is tough—its 10-K alone weaves antimicrobial toxicology, EPA approvals, and patent minutiae into hundreds of pages. If you have ever wondered where to locate Pure Bioscience insider trading Form 4 transactions or the latest R&D spending footnotes, you are not alone.
Stock Titan turns that complexity into clarity. Our AI reads every Pure Bioscience quarterly earnings report 10-Q filing the moment it hits EDGAR, delivering plain-English highlights of revenue from SDC disinfectants, cash-burn trends, and regulatory milestones. Need governance intel? We surface Pure Bioscience proxy statement executive compensation figures alongside peer benchmarks and flag Pure Bioscience executive stock transactions Form 4 in real time. Investors searching for Pure Bioscience SEC filings explained simply can drill into:
- 10-K—our "Pure Bioscience annual report 10-K simplified" summary points out antimicrobial market size assumptions and patent expiry timelines.
- 8-K—see Pure Bioscience 8-K material events explained whenever new distribution agreements or FDA feedback are announced.
- Form 4—instant alerts on Pure Bioscience Form 4 insider transactions real-time so you can gauge management conviction.
Whether you are modeling cash runway or benchmarking sustainability claims, our platform equips you with Pure Bioscience earnings report filing analysis in minutes, not hours. Start understanding Pure Bioscience SEC documents with AI today and turn dense biotech disclosures into actionable insight.
PURE Bioscience, Inc. has called its 2026 annual stockholder meeting for February 17, 2026 at 10:30 a.m. local time in Huntington Beach, California. Stockholders of record as of December 22, 2025, when 111,886,485 shares of common stock were outstanding, will vote on four key items.
They are being asked to elect seven directors, ratify Weinberg & Company, P.A. as independent auditor for the fiscal year ending July 31, 2026, approve on an advisory basis the compensation of named executive officers, and approve an amendment to the Certificate of Incorporation to increase authorized common shares from 200,000,000 to 250,000,000. As of December 22, 2025, a total of 176,722,446 shares were outstanding or reserved under options, RSUs, convertible debt and the 2024 Equity Incentive Plan, so the additional authorization is intended to provide flexibility for future financings, equity compensation and other corporate purposes. The Board recommends voting in favor of all proposals.
PURE Bioscience, Inc. has called its 2026 annual meeting for February 17, 2026 in Huntington Beach, CA. Stockholders will vote on four key items: electing seven directors, ratifying Weinberg & Company, P.A. as auditor for the year ending July 31, 2026, holding a non-binding advisory vote on executive compensation, and approving an amendment to increase authorized common stock from 200,000,000 to 250,000,000 shares.
The company explains that it relies on equity and convertible debt financings to fund operations and raised $1,015,000, $1,785,000 and $2,000,000 of convertible debt in fiscal 2023, 2024 and 2025. It argues that additional authorized shares would provide flexibility for future capital raising, acquisitions and equity awards. Executive pay is positioned as modest, with voluntary salary reductions for senior leaders, no cash bonuses in 2024 or 2025, and compensation heavily tied to stock options.
The Board highlights its governance structure, independent Audit and Compensation Committees, director qualifications, and insider trading and ethics policies. It unanimously recommends voting FOR all director nominees and FOR Proposals 2, 3 and 4.
PURE Bioscience, Inc. reported results for the three months ended October 31, 2025, with modest sales growth but ongoing losses and a weak balance sheet.
Total revenue reached
Despite these improvements, PURE recorded a net loss of
PURE Bioscience, Inc. filed a current report to notify investors that it has issued a press release announcing financial results for its fiscal first quarter ended October 31, 2025. The press release, dated December 15, 2025, is included as Exhibit 99.1 and contains details about the company’s operations and financial condition for that period.
The company explains that this information is being furnished rather than filed, so it is not subject to certain liability provisions under the Securities Exchange Act and is not automatically incorporated into other SEC documents.
Pure Bioscience, Inc.11/17/2025. He directly holds 12,998 shares of Pure Bioscience common stock. In addition, he holds several stock option awards giving him the right to buy common shares at exercise prices ranging from
PURE Bioscience, Inc. announced a leadership change in its executive team. Jeffrey Kitchell has been appointed as the company’s President, effective November 17, 2025, while continuing in his existing role as Corporate Secretary. Robert Bartlett remains Chief Executive Officer, principal executive officer, and a member of the board, but no longer holds the President title.
Kitchell, age 55, has been Vice President of Operations since April 2023 and has served as Corporate Secretary since 2019. He has been with the company since 2001 in a variety of roles overseeing day-to-day operations, legal affairs, and intellectual property, and holds a Bachelor’s degree in Business Administration from the University of Phoenix. His compensation terms are expected to follow the company’s standard officer indemnification and benefit programs, with no new special arrangements or related-party relationships disclosed.
PURE Bioscience, Inc. filed its annual report for the year ended July 31, 2025. The company reported net product sales of $2.20 million, up from $1.96 million in 2024, and a net loss of $2.4 million versus a $3.4 million loss last year. Cash was $334,000 as of July 31, 2025, and auditors expressed substantial doubt about the company’s ability to continue as a going concern.
The business focuses on proprietary silver dihydrogen citrate (SDC) antimicrobial products, including PURE Hard Surface (EPA-registered) and PURE Control (FDA Food Contact Notifications for poultry and produce). Customer concentration remains notable; the largest customer represented 18% of net product sales in 2025. As of October 29, 2025, there were 111,886,473 shares outstanding. The company completed a private placement of convertible debt with $2.0 million in net proceeds during fiscal 2025 and indicates the need for additional capital to fund operations.
PURE continues to pursue food-safety markets through distributors and partnerships while navigating extensive regulatory requirements from the EPA, FDA, USDA and foreign authorities.
PURE Bioscience (PURE)
FAQ
What is the current stock price of Pure Bioscience (PURE)?
What is the market cap of Pure Bioscience (PURE)?
